We recently published an article titled These 10 Stocks Moved the Market This Week, Here’s Why. In this article, we are going ...

Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...

Shares of online health platform Hims & Hers Health soared Tuesday after the company announced a partnership with Novo ...

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy ...

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy ...